Clinicopathologic and prognostic significance of SATB1 in cutaneous malignant melanoma

Journal of Dermatological Science

Volumn 64, Issue 1, 2011, Pages 39-44

  Chen, Hongxiang ^a,b   Takahara, Masakazu ^a   Oba, Junna ^a   Xie, Lining ^a   Chiba, Takahito ^a   Takeuchi, Satoshi ^a   Tu, Yating ^b   Nakahara, Takeshi ^a   Uchi, Hiroshi ^a   Moroi, Yoichi ^a   Furue, Masutaka ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Cutaneous malignant melanoma; SATB1

Indexed keywords

REGULATOR PROTEIN; SPECIAL AT RICH SEQUENCE BINDING PROTEIN 1; UNCLASSIFIED DRUG;

ADULT; AGE; ARTICLE; CANCER GROWTH; CANCER MORTALITY; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DISTANT METASTASIS; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MALE; MELANOMA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SEX DIFFERENCE; SKIN CANCER; SKIN ULCER; SKINFOLD THICKNESS;

AGED; BIOPSY; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHATIC METASTASIS; MALE; MATRIX ATTACHMENT REGION BINDING PROTEINS; MELANOMA; MIDDLE AGED; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; SKIN NEOPLASMS; TREATMENT OUTCOME;

EID: 80052363216     PISSN: 09231811     EISSN: 1873569X     Source Type: Journal    
DOI: 10.1016/j.jdermsci.2011.06.007     Document Type: Article

References (31)

1. Rager E.L., Bridgeford E.P., Ollila D.W. Cutaneous melanoma: update on prevention, screening, diagnosis, and treatment. Am Fam Physician 2005, 72:269-276.
2. Bhatia S., Tykodi S.S., Thompson J.A. Treatment of metastatic melanoma: an overview. Oncology (Williston Park) 2009, 23:488-496.
3. Vahrmeijer A.L., de Velde C.J.v., Hartgrink H.H., Tollenaar R.A. Treatment of melanoma metastases confined to the liver and future perspectives. Dig Surg 2008, 25:467-472.
4. Karbowniczek M., Spittle C.S., Morrison T., Wu H., Henske E.P. mTOR is activated in the majority of malignant melanomas. J Invest Dermatol 2008, 128:980-987.
5. Lasithiotakis K.G., Sinnberg T.W., Schittek B., Flaherty K.T., Kulms D., Maczey E., et al. Combined inhibition of MAPK and mTOR signaling inhibits growth, induces cell death, and abrogates invasive growth of melanoma cells. J Invest Dermatol 2008, 128:2013-2023.
6. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Murray T., et al. Cancer statistics, 2008. CA Cancer J Clin 2008, 58:71-96.
7. Walbert T., Gilbert M.R. The role of chemotherapy in the treatment of patients with brain metastases from solid tumors. Int J Clin Oncol 2009, 14:299-306.
8. Jovanovic B., Krockel D., Linden D., Nilsson B., Egyhazi S., Hansson J. Lack of cytoplasmic ERK activation is an independent adverse prognostic factor in primary cutaneous melanoma. J Invest Dermatol 2008, 128:2696-2704.
9. Dai D.L., Wang Y., Liu M., Martinka M., Li G. Bim expression is reduced in human cutaneous melanomas. J Invest Dermatol 2008, 128:403-407.
10. Bafaloukos D., Gogas H. The treatment of brain metastases in melanoma patients. Cancer Treat Rev 2004, 30:515-520.
11. Wojas-Pelc A., Rajzer L., Jaworek A., Wozniak W. The latest diagnostical methods and therapy in melanoma. Przegl Lek 2006, 63:674-680.
12. Hilmi C., Larribere L., Giuliano S., Bille K., Ortonne J.P., Ballotti R., et al. IGF1 promotes resistance to apoptosis in melanoma cells through an increased expression of BCL2, BCL-X(L), and survivin. J Invest Dermatol 2008, 128:1499-1505.
13. Wang W., Edington H.D., Rao U.N., Jukic D.M., Wang H., Shipe-Spotloe J.M., et al. STAT3 as a biomarker of progression in atypical nevi of patients with melanoma: dose-response effects of systemic IFNalpha therapy. J Invest Dermatol 2008, 128:1997-2002.
14. Houben R., Vetter-Kauczok C.S., Ortmann S., Rapp U.R., Broecker E.B., Becker J.C. Phospho-ERK staining is a poor indicator of the mutational status of BRAF and NRAS in human melanoma. J Invest Dermatol 2008, 128:2003-2012.
15. Han H.J., Russo J., Kohwi Y., Kohwi-Shigematsu T. SATB1 reprogrammes gene expression to promote breast tumour growth and metastasis. Nature 2008, 452:187-193.
16. Notani D., Gottimukkala K.P., Jayani R.S., Limaye A.S., Damle M.V., Mehta S., et al. Global regulator SATB1 recruits beta-catenin and regulates T(H)2 differentiation in Wnt-dependent manner. PLoS Biol 2010, 8:e1000296.
17. Zhao X.D., Ji W.Y., Zhang W., He L.X., Yang J., Liang H.J., et al. Overexpression of SATB1 in laryngeal squamous cell carcinoma. ORL J Otorhinolaryngol Relat Spec 2010, 72:1-5.
18. Li Q.Q., Chen Z.Q., Xu J.D., Cao X.X., Chen Q., Liu X.P., et al. Overexpression and involvement of special AT-rich sequence binding protein 1 in multidrug resistance in human breast carcinoma cells. Cancer Sci 2010, 101:80-86.
19. Zhou L.Y., Liu F., Tong J., Chen Q.Q., Zhang F.W. Expression of special AT-rich sequence-binding protein mRNA and its clinicopathological significance in non-small cell lung cancer. Nan Fang Yi Ke Da Xue Xue Bao 2009, 29:534-537.
20. Patani N., Jiang W., Mansel R., Newbold R., Mokbel K. The mRNA expression of SATB1 and SATB2 in human breast cancer. Cancer Cell Int 2009, 9:18.
21. Russo J., Han H.J., Kohwi Y., Kohwi-Shigematsu T. New advances in breast cancer metastasis. Womens Health (Lond Engl) 2008, 4:547-549.
22. Balch C.M., Soong S.J., Gershenwald J.E., Thompson J.F., Reintgen D.S., Cascinelli N., et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 2001, 19:3622-3634.
23. McGovern V.J., Shaw H.M., Milton G.W., McCarthy W.H. Ulceration and prognosis in cutaneous malignant melanoma. Histopathology 1982, 6:399-407.
24. Richon V.M. A new path to the cancer epigenome. Nat Biotechnol 2008, 26:655-656.
25. Dickinson L.A., Joh T., Kohwi Y., Kohwi-Shigematsu T. A tissue-specific MAR/SAR DNA-binding protein with unusual binding site recognition. Cell 1992, 70:631-645.
26. Gotzmann J., Meissner M., Gerner C. The fate of the nuclear matrix-associated-region-binding protein SATB1 during apoptosis. Cell Death Differ 2000, 7:425-438.
27. Nie H., Maika S.D., Tucker P.W., Gottlieb P.D. A role for SATB1, a nuclear matrix association region-binding protein, in the development of CD8SP thymocytes and peripheral T lymphocytes. J Immunol 2005, 174:4745-4752.
28. Agrelo R., Souabni A., Novatchkova M., Haslinger C., Leeb M., Komnenovic V., et al. SATB1 defines the developmental context for gene silencing by Xist in lymphoma and embryonic cells. Dev Cell 2009, 16:507-516.
29. Mai J.C., Ellenbogen R.G. SATB1: the convergence of carcinogenesis and chromatin conformation. Neurosurgery 2008, 63:N6.
30. Zhang J., Ma C., Han X., Durrin L.K., Sun Y. The bcl-2 major breakpoint region (mbr) possesses transcriptional regulatory function. Gene 2006, 379:127-131.
31. Cai R., Xu W., Dai B., Cai X., Xu R., Lu J. SATB1 binds an intronic MAR sequence in human PI3kgamma in vitro. Mol Biol Rep 2010, 37:1461-1465.